Moderna (MRNA) Reports Q1 Revenues Below Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates
May 8, 2019 7:00 AM EDTRare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has five rare disease programs in its pipeline
Immuno-Oncology: Two personalized cancer vaccine (PCV) abstracts to be presented at the 2019 ASCO Annual Meeting
Infectious Diseases: Merck submitted an IND for mRNA-1172, a more potent RSV vaccine development candidate; development paused for first RSV candidate, mRNA-1777
Ended quarter with $1.55 billion in cash, cash equivalents and investments
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq:... More
